Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2008 Aug;58(8):2219-24.
doi: 10.1002/art.23634.

Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis

Joel Rosenbloom  1 , Sergio A Jiménez
Affiliations
Editorial

Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis

Joel Rosenbloom et al. Arthritis Rheum. 2008 Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. TGF-β signaling pathways critical for the fibrotic response
Illustrated are two canonical Smad pathways originating from two representative tetrameric receptors. After TGF-β binding, the TGFβRII receptor recruits a type1 receptor (TGFβRI) and activates it by phosphorylation. Alk-5 then specifically phosphorylates receptor-regulated Smad 2 and Smad3 whereas Alk-1 phosphorylates Smad1 (Smad5 and Smad8, also activated by Alk-1, are not illustrated). The receptor Smads then complex with Co-Smad4 resulting in their transport to the nucleus where they cooperate with other factors to regulate transcription of critical genes, here represented by CTGF and α2(I) collagen. Also illustrated is a non-canonical pathway resulting in the activation of c-Abl. As pictured, imatinib blocks the activity of c-Abl, effectively inhibiting the fibrotic response although the events downstream of c-Abl are presently unknown. Imatinib also blocks the phosphorylation of Smad1, but here also the pathway is unknown.
See this image and copyright information in PMC

Comment on

References

    1. Varga J, Abraham D. Systemic Sclerosis: A prototypic multi-system fibrotic disorder. J Clin Invest. 2007;117:557–567. - PMC - PubMed
    1. Jimenez SA, Derk CT. Following the molecular pathways toward and understanding of the pathogenesis of Systemic Sclerosis. Ann Int Med. 2004;140:37–50. - PubMed
    1. Gharakee-Kermani M, Phan SH. Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. Curr Pharm Des. 2005;11:3943–3971. - PubMed
    1. Tskada S, Parson CJ, Rieppe RA. Mechanisms of liver fibrosis. Clin Chim Acta. 2006;364:33–60. - PubMed
    1. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006;69:213–217. - PubMed

MeSH terms

Substances